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Abstract
Human Papillomavirus (HPV) 16 E7 protein promotes the transformation of HPV infected epithelium to malignancy. Here,
we use a murine model in which the E7 protein of HPV16 is expressed as a transgene in epithelium to show that mast cells
are recruited to the basal layer of E7-expressing epithelium, and that this recruitment is dependent on the epithelial
hyperproliferation induced by E7 by inactivating Rb dependent cell cycle regulation. E7 induced epithelial hyperplasia is
associated with increased epidermal secretion of CCL2 and CCL5 chemokines, which attract mast cells to the skin. Mast cells
in E7 transgenic skin, in contrast to those in non-transgenic skin, exhibit degranulation. Notably, we found that resident
mast cells in E7 transgenic skin cause local immune suppression as evidenced by tolerance of E7 transgenic skin grafts when
mast cells are present compared to the rejection of mast cell-deficient E7 grafts in otherwise competent hosts. Thus, our
findings suggest that mast cells, recruited towards CCL2 and CCL5 expressed by epithelium induced to proliferate by E7,
may contribute to an immunosuppressive environment that enables the persistence of HPV E7 protein induced pre-
cancerous lesions.
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Introduction
Cervical and other anogenital cancers represent around 5% of
all cancers, and are mostly due to infection of anogenital
epithelium by one of more than 15 recognized ‘‘high risk’’ human
papillomaviruses (HPV) [1]. Worldwide, ,50% of sexually active
women are believed to become infected by HPV16, the HPV
genotype of highest risk, during their lifetime. Although most high
risk HPV infections spontaneously regress, 1 to 2% of infected
subjects develop persistent infection, which can progress to pre-
cancerous lesions, and to cervical cancer if untreated [2].
Mast cells (MCs) are an important subset of immune cells, often
considered as the first responders to opportunistic pathogens and
allergens [3,4]. Defined by the expression of two surface markers,
the receptor for IgE (FceRI) and the receptor for stem cell factor
(SCF) c-Kit, MCs are distributed at various densities below
epithelial surfaces that interface with the external environment
such as in the skin, airways and gastrointestinal tract, where they
are strategically placed to rapidly alert the inflammatory infantry
when required. In HPV associated cancers, MCs occur in HPV
induced premalignant CIN 2/3 lesions at twice the frequency
observed in normal cervix [5]. Most CIN2/3 lesions, as well as
cervical cancers, are known to be associated with infection of high-
risk HPVs [6,7]. In this study, we used HPV16-K14.E7 transgenic
mice, in which sustained expression of HPV16 E7 protein in
keratinocytes mimics pre-cancerous lesions caused by HPV
infection, to address three important questions. Firstly, does
HPV16 E7 expression recruit MCs toward the epithelium?
Secondly, what mechanistic pathway is involved in this process?
And thirdly, do MCs recruited juxtaposed to the epithelium by
HPV16 E7 expression mediate local immune suppression?
We show that MCs are recruited preferentially to the basal layer
of HPV16 E7 expressing epithelium, that this recruitment is
dependent on HPV16 E7 induced epithelial hyperproliferation,
and that it is likely MCs are recruited by a CCL2/CCL5
dependent mechanism. Using skin graft experiments in which
HPV16 E7 expressing skin containing or lacking MCs is
transferred onto wild-type C57BL/6 mice, in which we have
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previously demonstrated that graft rejection is CD8 T cell
mediated, enhanced by IL-1 and cd T cells, and hindered by
passenger NKT cells in E7 transgenic skin, but not by regulatory T
cells, [8–11], we now show that MCs make a key contribution to
the immunosuppressive environment imposed by HPV16 E7-
expression.
Results
HPV16-E7 expressing ear skin is hyperplastic and highly
infiltrated by mast cells
K14.E7 transgenic mice (E7 mice) express the HPV16 E7
oncoprotein in epidermal keratinocytes under the control of the
keratin 14 promoter. These mice are characterized by epidermal
and dermal thickening, with an extensive dermal lymphoid
infiltrate (Fig. 1A, B) consisting of an increased number of T
cells [8], NKT cells [12] compared to C57BL/6 (C57) mice. Based
on our previous findings that FoxP3+ T regulatory cells are not
required to inhibit CD8 T cell function in HPV16 E7 skin graft
tolerance [10], we hypothesized that other cells, along with NKTs,
could interfere with HPV infection resolution. MCs represent one
such population as there is important new evidence that they have
anti-inflammatory functions in certain settings [13–16].
Mice transgenic for the entire genome of HPV16 demonstrate
increased numbers of MCs in skin relative to non-transgenic
animals [17]. To determine whether this was a consequence of E7
expression and associated epidermal hyperplasia, we assessed MC
numbers in the dermis of E7 and wild-type skin by metachromatic
toluidine blue staining (Fig. 1C, D). Wild-type skin showed
detectable MCs (mean =27.96 cells per mm cartilage length)
distributed predominantly at the dermal/hypodermal interface
and sparsely in the upper dermis (Fig. 1C; bottom panel),
whereas E7 skin exhibited significantly higher numbers of MCs
tightly juxtaposed to the basal layer of the epidermis (mean
= 106.74 cells per mm cartilage length, p= 0.0007) (Fig. 1C;
upper panel and Fig. 1D).
HPV16-E7 driven hyperplasia is responsible for increased
mast cell infiltration
To determine whether E7 expression or the epithelial hyper-
plasia resulting from E7 expression is the primary cause of the
increased numbers of MCs in E7 skin, we tested the impact of E7-
induced hyperplasia on MC numbers. This was achieved using
mice double transgenic for E7 and mutant Rb (E7.Rbmut) in which
E7 cannot disrupt normal cell cycle regulation by segregating Rb
[18]. We confirmed the lack of hyperplasia in E7.Rbmut skin when
compared to E7 mouse skin, which has unmodified Rb (Fig. 2A
bottom panel). The density of MCs in E7.Rbmut skin was
decreased to the level of C57 mouse skin and Rbmut skin not
transgenic for E7, as confirmed by analysis of MC numbers
(Fig. 2B) (mean = 97.88, 33.58, 33.93 and 31.10 MCs/mm
cartilage length for E7.Rbwt, E7.Rbmut, Rbwt and Rbmut,
respectively, p = 0.0002). These findings strongly suggest that E7-
mediated pRb inactivation is important for the recruitment of
MCs to the epidermis.
Mast cells are recruited to HPV16-E7 ear skin
The accumulation of MCs in hyperplastic skin associated with
E7 expression might be due to prolonged survival, to local
proliferation, or to increased recruitment [19]. To determine
whether E7 induced epithelial hyperplasia induces MC prolifer-
ation, we stained serial ear pinna sections with toluidine blue to
detect MCs and with PCNA to detect cell proliferation. Purple
MCs and red PCNA stain did not co-localize (Fig. S1A) in wild-
type or in E7 skin. To confirm this result, we cultured CFSE-
labeled bone marrow-derived cultured MCs (BMCMCs) in
medium alone, or with E7 and wild-type ear skin explant culture
supernatants (all supplemented with IL-3) for 24, 48 and 72 h.
Although BMCMCs proliferated in culture (Fig. S1B), their
numbers were not different between cultures exposed to E7 or
wild-type supernatants (Fig. S1C). Thus, there was no evidence
that supernatants derived from hyperplastic E7 transgenic skin
contained factors at levels high enough to induce MC prolifera-
tion.
To test whether E7 skin specifically recruited MCs, we
examined the production of three relevant chemokines SCF,
CCL2 (MCP-1) and CCL5 (Rantes). Although SCF mRNA
expression was comparable between full thickness (dermis and
epidermis) normal C57 versus E7 mouse skin, levels of CCL2
mRNA and CCL5 mRNA were significantly increased or
decreased, respectively, in E7 skin (Fig. 3A). By contrast, E7
epidermis alone expressed lower levels of SCF mRNA (p,0.0001),
and higher levels of both CCL2 and CCL5 than non-transgenic
skin (p,0.0001) (Fig. 3B).
To determine whether MCs exposed to E7 skin might be
induced to express the receptors for the chemokines upregulated in
E7 skin, we co-cultured BMCMCs with ear skin explant
supernatants for 72 h. BMCMCs exposed to E7 supernatants
upregulated CCR2 mRNA (CCL2 receptor), and some but not all
BMCMCs expressed CCR1 or CCR5 (CCL5 receptors)
(Fig. 3C). Further, CCR2 mRNA was also expressed at higher
levels by MCs sorted from E7 ear skin than by BMCMCs
(Fig. 3D).
To assess the migration capacity of MCs, we used BMCMCs in
a migration assay. We first confirmed that BMCMCs migrate
towards the direct ligand of cKit, SCF, as previously reported [20].
Then, we observed that BMCMCs migrate towards E7 ear skin
explant supernatant, but not towards medium only or 98uC heated
supernatant, suggesting that thermosensitive compounds attract
BMCMCs (Fig. 4A). Moreover, BMCMCs do not migrate when
the supernatant is added to the upper well chamber; demonstrat-
ing migration is due to chemotaxis rather than enhanced
chemokinesis. Finally, we showed that this migration towards ear
skin supernatant can be abrogated by blocking CCL2 and CCL5,
together or alone (Fig. 4A).
C57BL/6-KitW-sh/W-sh mice have an inversion mutation that
affects transcriptional regulatory elements upstream of the c-kit
transcription start site on mouse chromosome 5 which impairs Kit
function and results in a profound mast cell-deficiency in adult
Author Summary
Worldwide, around 50% of sexually active women are
believed to become infected by Human papillomavirus
type 16, the major cause of cervical cancer, and 2% will
remain infected and therefore at lifetime risk of developing
cancer. Why some women remain infected is unknown.
Here we used a mouse engineered to express the HPV16
protein (E7) in skin, which drives development of pre-
cancer lesions. This protein induces skin thickening, and
the thickened skin releases molecules that attract mast
cells. We show further that these cells locally suppress the
function of the immune effector cells that can reject E7
expressing skin. We believe that targeting mast cells or
impairing their attraction to the HPV infected tissue might
therefore reduce the risk of cervical cancer for women
infected with HPV16 by enabling them to clear their
chronic infection.
Immunosuppressive Mast Cells in HPV Expressing Skin
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mice [21,22]. To further establish in vivo that MCs are recruited
preferentially to E7-expressing skin, we performed adoptive
transfer i.v. of 1.46107 BMCMCs to KitW-sh/W-sh and E7.KitW-
sh/W-sh mice. The recipient KitW-sh/W-sh and E7.KitW-sh/W-sh mice
exhibited successful transfer of MC populations as evidenced by a
substantial MC infiltration in the spleen of each mouse (Fig. S2)
[21]. Notably, we observed preferential recruitment of the injected
MCs to E7-expressing, as opposed to non-transgenic, ear skin
tissues (Fig. 4B, C).
Altogether, these data suggest that BMCMCs are preferentially
recruited to E7-expressing epidermis by a mechanism that is likely
to involve the local production of CCL5 and CCL2.
Mast cells are more degranulated in HPV16-E7 ear skin
Following the observation that BMCMCs were recruited to
E7.KitW-sh/W-sh ear skin, we also noticed their close contact with
the basal layer of the epidermis in both the engrafted E7.KitW-sh/
W-sh mice and the E7 mice. Fully granulated MCs can be identified
as dark purple stained cells using toluidine blue, while degranu-
lated MCs are light purple stained with some exterior granules
[23,24]. In E7 skin, we observed that the closer MCs were to the
keratinocytes, the more degranulated they appeared (Fig. 1C and
Fig. S3A). Using a heparin stain, we assessed the degranulation
status of MCs in E7 and C57 skin and we showed that E7 skin
contained more degranulated MCs (Fig. S3B). Although the
Figure 1. MCs are highly represented in E7 skin. A) Ear thicknesses were measured in naive age-matched E7 and C57 mice using a micrometer
gauge (n = 10 and 11, respectively, ****p,0.0001). B) Representative images of E7 and C57 ear skin analyzed by H&E stain (scale bar = 20 mm). C)
Representative images of E7 and C57 ear skin analyzed by toluidine blue stain, which is specific for MCs (purple, scale bar = 100 mm (left) and 20 mm
(right)). D) MC numbers expressed per mm cartilage length (n = 8 E7 mice and n=6 C57 mice, respectively; ***p,0.001).
doi:10.1371/journal.ppat.1004466.g001
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mechanism(s) underlying MC activation in this setting are yet to be
fully elucidated, a potential candidate is endothelin-1 (ET-1) which
can induce MC degranulation [25] and its expression is
significantly elevated in E7 ear skin (Fig. S4). Thus, these data
suggest that interaction of MCs with the basal epidermal layer in
E7 skin, or with a factor secreted by the epidermis such as ET-1,
can cause activation of MCs, with release of granule contents.
Mast cells play a role in the immunosuppressive
environment in HPV16 E7 skin
MCs can regulate local immune responses to tumors [17,26]
and allografts [27–29]. E7 skin grafted onto syngeneic, non-
transgenic animals is not rejected [12]. To determine whether
MCs contribute to the local immunoregulatory environment in
this model, we grafted E7 skin with (E7) or without (E7.KitW-sh/W-
sh) MCs onto syngeneic immunocompetent C57BL/6 recipients.
E7 skin grafts without MCs were rejected within 3 weeks in 8 out
of 9 mice, whilst E7 skin grafts with MCs, and non-transgenic skin
with or without MCs, were not rejected (Fig. 5A). 28 days after
grafting, host-derived MCs had repopulated the MC-deficient
grafts, with the highest infiltration occurring within any remaining
E7.KitW-sh/W-sh skin (Fig. 5B and 5C), confirming the results of
Fig. 4. These dataset demonstrate that MCs have a locally
immunosuppressive effect on graft rejection, a regulatory function
that might reduce CD8 T cell activity that we have previously
shown to be necessary for graft rejection [8–11].
Discussion
Infection of the cervix with high risk HPVs is necessary though
not sufficient for the development of cervical cancer, and
continued expression of HPV E6 and E7 non-structural proteins
is the hallmark of HPV transformed epithelium [2]. Here we show,
using a mouse with persisting epithelial expression of the E7
protein of HPV16, the high risk HPV most often associated with
cervical cancer, that MCs are recruited to E7-expressing
hyperplasic epithelium in high numbers, and that such recruitment
is dependent on the ability of E7 to sequester Rb protein. We show
further that degranulated MCs are found juxtaposed to the basal
keratinocyte layer and are attracted to the skin by chemokines
released by hyperproliferative epithelium, and that this accumu-
lation might hinder, directly or indirectly, CD8 cytotoxic T cell
mediated rejection of E7 expressing epithelium [8–11].
In mice transgenic for the whole HPV16 early gene region
expressed from a K14 promoter, progression of epithelial
hyperplasia and papillomatosis to dysplasia correlates with MC
accumulation and activation [30,31], but the mechanisms
promoting the accumulation of MCs are poorly defined. Many
chemoattractants are involved in the recruitment of MCs into
tissues [32]. MCs are recruited to tumors by tumor-derived SCF
[33], engaging a signaling pathway for MC differentiation,
migration, maturation and survival [34]. In virus associated
tumors, additional chemokines, and their respective receptors
Figure 2. MC infiltration in ear skin is dependent on E7 hyperplasia. E7.Rbmut ear skin is not hyperplasic and contains normal MC numbers.
(A) Representative images of E7.Rbwt and E7.Rbmut ear skin by toluidine blue stain (original magnification6400, scale = 50 mm). (B) MC number per
mm cartilage length (n = 3 in each group). ***p,0.001 by unpaired t-test for indicated comparison. Rbwt are same as C57.
doi:10.1371/journal.ppat.1004466.g002
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expressed on the cell surface of circulating bone marrow-derived
progenitors [35] or resident mature MCs, are likely to provide
migratory or proliferative signals. Coussens et al. [17,36,37]
observed, in a HPV16 transgenic mouse in which the entire early
gene region of HPV16 was expressed in the skin under the K14
promoter, that there was infiltration of MCs and increased
angiogenesis in association with keratinocyte proliferation and
increased skin thickness. To study the contribution of MCs,
Coussens et al. attempted to use c-kit mutant KitW/W-v mice that
exhibit a profound loss of c-kit activity, resulting in a systemic MC
and basophil deficiency, as well as other phenotypic abnormalities
including anemia, neutropenia and sterility [14]. A single KitW/W-v
MC-deficient mouse expressing HPV16 early genes was the sole
survivor of 89 KitW/W-v MC-deficient pups among 700 littermates,
precluding analysis of the role of MCs in HPV associated
pathology. To establish a role for MCs in conferring local
immunosuppression or promoting local pathology in HPV
transformed epithelium, we therefore studied a mouse which
expresses HPV16 E7, the single HPV early gene most relevant to
cervical epithelial progression to cancer, from a keratin 14
promoter. We used a C57BL/6-KitW-sh/W-sh mouse, in which an
inversion mutation of the transcriptional regulatory elements
disrupts Kit transcription leading, as in the KitW/W-v mouse, to a
profound systemic MC deficiency. This KitW-sh/W-sh MC-deficient
strain exhibits a neutrophilia [22,38] rather than the neutropenia
of KitW/W-v mice, and otherwise exhibits a much reduced range of
phenotypic abnormalities [21,22,38]. When crossed with our
HPV16 E7 mice, the C57BL/6-KitW-sh/W-sh mice produce viable
E7 transgenic and MC-deficient offspring.
In our MC competent HPV16 E7 mice, we confirmed
Coussens’ observation of the accumulation of MCs in the dermis
[17], juxtaposed to the basal layer of the epidermis where E7 is
expressed. We therefore proceeded to establish the mechanism for
accumulation of MCs at that site. E7 expressed under the K14
promoter interacts with many proteins and also binds its main
target Rb inhibiting the sequestration of E2F family proteins, and
thus driving keratinocyte proliferation [8,18,21,39]. A mutation of
Rb is recognized that hinders binding of E7 but not of E2F
proteins [8]. E7.Rbmut mice, expressing E7 and this mutated Rb,
do not show the epithelial hyperplasia associated with E7
transgenic mice. We observed no increase in MCs in E7.Rbmut
mice, confirming that MC infiltration of the basal epidermis is
associated with HPV16 E7 induced epithelial hyperproliferation.
We have previously observed that IFNc is expressed in E7
transgenic mouse skin [12,40], and therefore chemokines express-
ing an IFN regulatory factor-1 response element in their non-
coding gene regions, such as CCL2 and CCL5 [41,42], represent
potential MC chemoattractants to E7 skin. We show here that
MCs migrate towards HPV16 E7-expressing ear skin explant
cultures, and that migration towards the supernatant of HPV16
E7-expressing ear skin cultures can be blocked by neutralizing
CCL2 and CCL5, which confirmed a role for these chemokines in
Figure 3. E7 epidermis produce CCL2 and CCL5 and MCs express the corresponding receptors. (A) C57 and E7 whole skin, or (B) C57 and
E7 epidermis, were analyzed for SCF, CCL5 (Rantes) and CCL2 (MCP-1) gene expression. Data are combined from 2 independent experiments. CCR1
and CCR5 (two Rantes receptors) and CCR2 (MCP-1 receptor) gene expression in (C) BMCMCs after 72 h culture in E7 or C57 ear skin culture
supernatant or medium (n= 10 different batches of BMCMCs; data are combined from 4 independent experiments. ND, not detectable) and (D) Mast
cells sorted from E7 ear skin (n = 6 independent experiments, each with 4 or 5 mice pooled per treatment). Gene expression was performed by real
time-PCR relative to the RL32 housekeeping gene. *p,0.05; **p,0.01; ***p,0.001; or ****p,0.0001 by unpaired t-test for indicated comparisons; ns
= not significant.
doi:10.1371/journal.ppat.1004466.g003
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recruiting MCs to HPV16 infected epithelium. Adoptive transfer
of BMCMCs repopulated the MC population in the ear skin of
MC-deficient HPV16 E7. KitW-sh/W-sh mice but not MC-deficient
KitW-sh/W-sh mice, demonstrating that expression of HPV16 E7
induces MC migration. High levels of CCL2 and CCL5
transcription associated with HPV16 E7 expression in skin are
consistent with the hypothesis that expression of these chemokines,
induced by E7, accounts for the MC infiltrate in E7 transgenic
mouse skin. To further decipher the role of Rb and epithelial
hyperproliferation in MC chemotaxis, future experiments will
determine whether CCL2 and CCL5 levels are concomitantly
decreased in Rbmut/PV16-K14.E7 Tg mouse epidermis.
As shown in Figure 1 and Supplemental Figure 3, those MCs
recruited to E7 skin appear more degranulated. Although the
mechanisms underlying MC degranulation at the interface with
HPV16 E7 epithelium are yet to be fully understood, production
Figure 4. MCs migrate towards CCL2 and CCL5 and are recruited to E7 ear skin. (A) 5 mm transwell assays were used to determine the mast
cells chemotaxis towards chemokines. Graphs represent the number of migrated FceRIa+ cKit+ BMCMCs towards C57 skin explant supernatants (left)
or E7 explant supernatants (right) in the presence of anti-CCL2 and/or anti-CCL5 blocking antibodies used at 10 mg/ml. 3 independent experiments
(B,C) KitW-sh/W-sh (Wsh) (n = 3) and E7.KitW-sh/W-sh (E7.Wsh) (n = 3) mice were reconstituted with 1.46107 BMCMCs i.v. or left untreated (E7.Wsh (n = 3)
and Wsh (n = 2)). 12 weeks later, mice were culled and MCs were identified in ear skin by (B) toluidine blue staining (top, scale bar = 50 mm and
bottom, scale bar = 20 mm) and expressed as (C) MC number per mm cartilage length. *p,0.01, by unpaired t-test for all indicated comparisons.
doi:10.1371/journal.ppat.1004466.g004
Immunosuppressive Mast Cells in HPV Expressing Skin
PLOS Pathogens | www.plospathogens.org 6 October 2014 | Volume 10 | Issue 10 | e1004466
of ET-1 by the virus affected epithelium [43] or by the
surrounding microenvironment in E7 transgenic mouse skin
(Fig. S4), and the ability of this peptide to promote tumor
invasion [44] as well as induce MC degranulation [25] represents
a potential means of MC activation in our current study. MC
degranulation typically involves release of pre-formed and stored
granule associated mediators [14], including histamine which can
contribute to systemic immunosuppression in response to UVB-
irradiation of the skin [45], and the tryptase mMCP6 which can
actively deplete the local environment of IL-6 to maintain skin
allograft tolerance [46]. The activated state of MCs in HPV16 E7
skin also indicates that MCs might be releasing de novo
synthesized mediators. We have shown that MC-derived IL-10
can curtail inflammation associated with certain settings of allergic
contact dermatitis and low-dose UVB irradiation of the skin [15].
More recently, other immunoregulatory roles for MC-IL-10 have
emerged, including an ability to reduce graft-versus-host-disease
independently of Tregs during hematopoietic cell transplantation
[16,47] and a capacity to drive tolerance in chronic bacterial
infection by suppressing humoral and cell-mediated immunity
[13]. However, while evidence from such studies supports the
notion that MC-IL-10, histamine or mMCP6 might be involved in
regulating immune responses in the HPV-infected microenviron-
ment, further work is required to determine which MC-derived
mediators specifically orchestrate local immune suppression in this
setting.
MCs are involved in many pathologies and a role in cancer has
been indicated (reviewed in [48], and [26,49,50]). The accumu-
lation of MCs in the vicinity of tumor tissue strongly correlates
with poor prognosis in many aggressive cancers, including
gastrointestinal [51,52] and pancreatic cancers [53] in humans,
and in mice. MCs can promote angiogenesis, tumor invasion,
immune suppression, and the recruitment of other immune cells
including regulatory T cells [29]. However, the role of MCs in
cervical cancer associated with HPV infection is largely unknown,
but in such a setting it is possible that MCs promote persistence of
infection by contributing to an immunosuppressive microenviron-
ment. MC prevalence at different anatomical sites is under genetic
control and can be influenced by extrinsic factors (e.g. extent of
sun exposure of the skin) [54]. Thus MC heterogeneity in
prevalence, as well as inter-individual differences in the microen-
vironments in which the MCs reside might be factors that
contribute to allowing persistence of HPV infection, and hence
increased risk of cancer, in only 2% of those infected. Persisting
HPV infection is not resolved by the current preventive vaccines
[55,56], and new therapeutic strategies are needed to treat the
many women at risk of cervical cancer through persisting HPV
infection [57]. A specific immunotherapy against E6 and/or E7
Figure 5. MCs are immunosuppressive in E7 environment. (A) C57 mice were double grafted with C57 syngeneic ear skin (n = 9), and either
KitW-sh/W-sh (Wsh) ear skin (n = 9) or E7. KitW-sh/W-sh (E7.Wsh) ear skin (n = 9). Control E7 ear skin (n = 6) are tolerated. Kaplan-Meier survival curves show
the median graft survival. ****p,0.0001 using a log-rank test. Data are combined from 3 independent experiments. (B) Representative graft histology
of C57, Wsh and one remaining E7.Wsh graft at day 90 by toluidine blue staining (scale bar = 100 mm). (C) MCs per mm of graft tissue at day 28 in C57
(n = 4), Wsh non-rejected (n = 4) and E7.Wsh rejected (n = 3) grafts. (**p,0.01, by unpaired t-test).
doi:10.1371/journal.ppat.1004466.g005
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remains elusive [2,58,59], though whether HPV infection directly
suppresses aspects of the host immune response is largely
unknown [60]. Vaccine immunotherapy against an HPV16 E7
expressing non-small cell lung cancer (NSCLC) line has been
shown to be more effective with an anti-CCL2 blocking antibody
[61]. Taken together, our data suggest that HPV16 E7-expression
in the epithelium recruits MCs, which like tumor associated
macrophages [62] and myeloid suppressor cells [63] in other
malignant settings, appear to exhibit an immunosuppressive
function in the E7-influenced microenvironment. Thus, it is
plausible that CCL2 and/or CCL5 blockade might reduce such




C57BL/6 mice (C57) were obtained from the Animal Resources
Centre (ARC, Perth, Australia). HPV16 K14.E7 transgenic
C57BL/6 mice (E7 mice), in which E7 oncoprotein is expressed
under the K14 promoter were maintained locally at the Princess
Alexandra Hospital Biological Research Facility (BRF, Brisbane,
QLD, Australia) under specific pathogen-free conditions.
RbDLXCXE (Rbmut) mice and HPV16 K14.E7x-RbDLXCXE
(E7.Rbmut) mice on a mixed 129/FVB/C57 background have
been previously described [8,18] and were bred at the McArdle
Laboratory Cancer Center Animal Care Facility, USA, and
generously provided by PF Lambert lab, Madison, Wisconsin,
USA. Genetically c-kit mutant mast cell-deficient C57BL/6-KitW-
sh/+ mice backcrossed with C57BL/6J mice for 14 generations
were used as breeding pairs to produce mast cell-deficient
B6.KitW-sh/W-sh mice and were maintained at the IMVS Animal
Facility (Centre for Cancer Biology, Adelaide, SA, Australia
[21,64]). B6-KitW-sh/W-sh mice were crossed with E7 mice to
obtain mast cell-deficient mice expressing the HPV16-E7 onco-
protein (E7.KitW-sh/W-sh mice). All mice were sex matched for all
experiments and were used at 10 to 16 weeks of age. Experiments
were performed in compliance with the ethical guidelines of the
National Health and Medical Research Council of Australia, with
approval from the IMVS Animal Ethics Committee and the
University of Queensland Animal Ethics Committee.
Ear thickness was measured with a micrometer gauge (Ozaki
MFG) on anesthetized mice.
Mast cell isolation from ear skin
Ears were harvested and separated into dorsal and ventral
halves using forceps. For epidermal removal, the skin was
incubated epidermis-down in 1.2 mg/ml Dispase II (Roche) at
37uC. After an hour, the epidermal layer was peeled off the
dermis. To release cells, skin were torn into small fragments and
digested for 1 h in 1 mg/ml collagenase D, 0.5 mg/ml type 2
hyaluronidase and 20 ug/ml Dnase 1 (all from Roche) at 37uC.
Tissues were passed through a cell strainer and washed in PBS
containing 3% FBS. Isolated cells were then stained for flow
cytometry or cell sorting using anti-CD3 (clone 2C11, 1.0 mg/ml),
anti-CD45R/B220 (clone RA3-6B2, 1.0 mg/ml), and anti-CD117
(cKit clone 2B8, 1.25 mg/ml) antibodies from BD Pharmingen,
and anti-CD45.2 (clone 104, 0.5 mg/ml), anti-FceRIa (clone
MAR-1, 0.5 mg/ml) antibodies and streptavidin PE (0.4 mg/ml)
from eBioscience, and anti-CD11c (clone N418, 2.5 mg/ml) from
BioLegend. MCs were gated as CD45.2+, CD32, B2202,
CD11c2, cKit+ and FceR1a+. For mRNA isolation, sorted MCs
were directly collected into lysis buffer (Bioline ISOLATE II RNA
Micro Kit).
BM-derived cultured mast cells
As previously described [15,64], bone marrow cells were
collected from femurs and tibiae and cultured in DMEM
supplemented with 10% Fetal Calf Serum and a source of mouse
IL-3 which is necessary for MC differentiation and proliferation
(i.e. 20% WEHI-3 conditioned medium supplemented with
recombinant mouse IL-3 (R&D Systems) to consistently achieve
a total of 3–4 ng/mL IL-3). After 5 to 6 weeks .95% of the cells
were identified as MCs by May-Grunwald-Giemsa staining
histologically or by flow cytometry using anti-CD45.2+, cKit+
and FceRIa+ staining.
Adoptive transfer of BMCMCs
5 to 6 week old BMCMCs were washed twice in PBS and
1.46107 cells injected i.v. into KitW-sh/W-sh and E7. KitW-sh/W-sh
mice. 12 weeks after BMCMC transfer into the mice, ear skin and
spleen were collected to confirm the presence of MCs in these
tissues by toluidine blue staining and histological analysis, as
previously described [21].
Ear skin explant culture
Ears were collected from C57 or E7 mice on ice, split into
halves, and placed dermis side down in complete WEHI-
conditioned medium at 37uC. Medium was replaced after 1 h
and again after 3 h with 600 ml of fresh conditioned medium, to
reduce cell-death related release of cytokines and danger signals.
Ear explants supernatants were collected 20 h later and stored at
280 degrees until use.
For BMCMC culture with ear skin explant supernatants, 56105
BMCMCs were first labelled with 2.5 mM CFSE for 15 min at
37uC, and then washed twice with PBS. BMCMCs were then
seeded in 24 well plates in WEHI-conditioned medium and ear
skin explant supernatant (1:1) for 4, 24, 48 or 72 h, following
which cells were collected for mRNA extraction. CFSE dilution
was analyzed by flow cytometry within cKit+ FceRIa+ double-
positive cells. Samples with analyses below the assay detection level
were assigned a value of not detected (ND) for display and
statistical analysis.
Migration assay
Transwell migration assays were performed using 5 mm pore
size Transwell inserts (Corning, NY). 26105 3–6 week old
BMCMCs were placed in the top chamber in 100 ul of medium
without IL-3. Recombinant mouse SCF (RnD Systems) at 0–
100 ng/ml or E7/C57 ear skin explant culture supernatant
without IL-3 were placed in the bottom chamber. When indicated,
anti-CCL2/Rantes (clone 53405) or anti-CCL5/JE/MCP-1 (clone
123616) blocking antibodies from RnD Systems were added in the
bottom chamber at 10 mg/ml and the plate was then incubated at
37uC. Four hours later, cells were collected from the bottom
chamber and counted by trypan blue exclusion on a hemocytom-
eter, and phenotyped by flow cytometry for anti-CD45.2, anti-
FceRIa and anti-cKit expression.
Ear skin grafting
Donor ear skin was grafted onto recipient flanks as previously
described [12]. Briefly, dorsal and ventral surfaces of ear skin from
transgenic mice were placed onto the thoracic flank region of an
anesthetized C57BL/6 recipient. Grafts were held in place with
antibiotic-permeated gauze (Bactigras; Smith and Nephew,
London, U.K.) and bandaged with micropore tape and Flex-wrap
(Lyppard, Queensland, Australia). After 7 days, bandages were
removed and grafts were monitored three times a week for 4 weeks
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or longer. Graft rejection was assessed by a loss of distinct border
and signs of ulceration and/or necrosis to .80% of the graft area.
Histology on ear skin tissues
Mice were culled by CO2 inhalation and samples of ear pinnae
were fixed in 4% formalin. Samples were coded using a serial
number, so the evaluator was not aware of their identity and sent
to the histology facility to be embedded in paraffin (ensuring a
cross-sectional orientation) and cut as 4–6 mm sections. Sections
were then stained with toluidine blue, pH 1, for the detection of
mast cells (purple), with hematoxylin/eosin, alcian blue-safranin-O
or with Proliferating Cell Nuclear Antigen (PCNA, Sigma). Images
of coded samples were taken with a 206 microscope objective
(Nikon Brightfield, final magnification,6200). Field lengths (mm)
were determined using NIS-Element software (Nikon). Mast cells
were counted manually by image analysis using NIS-Element on 4
to 10 consecutive fixed fields of view along the entire length of ear
skin and calculated per mm cartilage length.
mRNA extraction and semi-quantitative real-time PCR
At collection, samples were snap-frozen in dry ice and stored at
280uC until mRNA extraction. Ear skin samples were then lysed
in RNase-free microtubes using Trizol (Sigma) and an IKA T10
Ultra-Turrax homogenizer, and incubated for 5 min at RT. Total
RNA extraction was performed as per manufacturer’s recommen-
dations. Briefly, 0.2 ml of mRNA-grade chloroform was mixed
with each sample and incubated for 2–3 min. Samples were
centrifuged 12000 rpm for 15 min at 4uC. The aqueous, colorless
phase containing RNA was then collected without disturbing the
white interphase and transferred into a fresh tube. RNA was
precipitated using cold 100% isopropanol (vol/vol), incubation for
10 min at RT and centrifugation 12000 rpm for 10 min at 4uC.
The RNA pellet was washed twice in 75% ethanol and air-dried
for 10–15 min before being dissolved in 10 ml of RNase/Dnase
free water at 55uC. Genomic DNA was digested using the Qiagen
RNase-free DNase kit (DNase kit; #79254). RNAs were then
quantified at 260/280 ratio by nanodrop spectrophotometry.
RNAs were stored at 280uC until used for retrotranscription. For
cell-sorted MCs, the Isolate II RNA Micro kit (Bioline) was used
following manufacturer’s instructions.
For reverse transcription, 500 ng of RNA was combined with
25 mM MgCl2, 25 mM dNTPs, oligoDT, RNase inhibitor, and
MuLV Taq polymerase in buffer (all from Applied Biosystems) for
25 min at 25uC, 60 min at 42uC and 5 min at 95uC. cDNAs were
stored at 220uC until used for PCR.
For semi-quantitative Real-Time PCR, samples were amplified
using a Sybr premix Taq II (TAKARA) following the manufac-
turer’s instructions. The amplification program was run on a
ABI7900 (Applied Biosystems) - 1630 sec at 95uC, 456 (5 sec
95uC and 30 sec at 60uC), followed by a dissociation stage (15 sec
at 95uC, 60 sec at 60uC, 15 sec at 95uC). For the detection of ET-
1, the following cycling conditions were performed: 1615 min at
95uC, 456 (15 sec 95uC, 15 sec at 55uC, 20 sec at 72uC), followed
by a hold of 30 sec at 72uC. Primers were designed using IDT
(Integrated DNA Technologies, www.idtdna.com) (Table S1).
Statistics
A non-parametric Mann-Whitney t-test or unpaired t-test were
used as indicated for assessment of differences between groups. A
Log-rank (Mantel-Cox) test was used to compare survival curves.
Differences were considered to be significant when the p value was
less than 0.05. Prism (GraphPad Software, La Jolla, CA) software
was used to prepare graphs and for statistical analysis.
Supporting Information
Figure S1 MCs do not proliferate in E7 ear pinnae. (A)
Representative images of PCNA or toluidine blue stained C57BL/
6-WT (C57) and E7 ears (scale bar = 20 mm). Arrow heads
indicate MCs in both PCNA and toluidine blue sections. (B) E7
ear explant supernatant does not induce increased BMCMC
proliferation. CFSE-labelled BMCMCs were cultured in E7 or
C57 ear skin culture supernatant or medium only for 24, 48 or
72 h and analyzed by flow cytometry for CFSE dilution. Data are
representative of 2 independent experiments. (C) After 72 h, live
and dead BMCMCs were counted (n= 10 different batches of
supernatants per group, 4 different BMDMCs batches). Data
expressed as mean + SEM and no significant differences were
observed between the groups using a non-parametric Mann-
Whitney statistical test.
(TIFF)
Figure S2 Evidence that MC populations successfully
engraft in recipient KitW-sh/W-sh and E7. KitW-sh/W-sh
mice.MCs (purple cells) identified in toluidine blue stained spleen
sections of C57 (n= 1), MC-deficient KitW-sh/W-sh (Wsh) (n = 1),
and in KitW-sh/W-sh (Wsh) (n = 3) or E7.KitW-sh/W-sh (E7.Wsh)
(n = 3) mice 12 weeks after i.v. administration of 1.46107 wild-type
BMCMCs. (A) MC number per mm2; and (B-D) representative
histological images of spleen sections from (B) MC-deficient KitW-
sh/W-sh (Wsh) and (C–D) BMCMC-engrafted E7.KitW-sh/W-sh
mice. B,C, scale bar = 1 mm and D, scale bar = 100 mm. Data
expressed as mean + SEM.
(TIFF)
Figure S3 MCs are more degranulated in E7 ear pinnae.
(A) Representative image of safranin stained MCs in an E7 mouse
ear pinna (scale bar = 10 mm). Degranulation of MCs indicated as
non-degranulated (none), partial or high. e, epidermis; d, dermis;
c, cartilage (B) Extent of MC degranulation expressed as the
percent of the total MC counted in ear skin sections of a total of
2.8 to 3.3 mm cartilage length. Data expressed as mean + SEM;
n=3 mice each of C57BL/6- WT or E7 genotype). *p,0.05; or
***p,0.001 for indicated comparisons by an unpaired Student’s t-
test with Welch’s correction.
(TIFF)
Figure S4 ET-1 gene transcript is upregulated in E7 ear
pinnae. C57 and E7 whole mouse skin were analyzed for ET-1
mRNA. Gene expression was performed by real time-PCR
relative to the RL32 housekeeping gene. Mice: 10–14 weeks of
age; data expressed as mean + SEM; n=12 mice/group *p,0.05
by unpaired t-test.
(TIFF)
Table S1 Primer sequences. Gene names, NCBI IDs and
forward and reverse sequences of the genes analysed in this study.
(DOCX)
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